Current studies are using monoclonal antibodies against PD-L1 and CTLA-4 to treat rare sarcomas, such as DDLPS and pleiomorphic liposarcoma (NCT02500797 and NCT03114527) or the effect of the PD-L1 inhibitor Durvalumab in combination with either Pazopanib (a TKI inhibitor) or Tremelimumab (a CTLA-4 inhibitor) in advanced STS (NCT03798106 and NCT02815995). This evidence concerns the gene CTLA4 and liposarcoma.